Magazin

2006-07-28

Pfizer's Champix(R) Receives Positive Opinion From CHMP for the Treatment of Smoking Cessation


New York (ots/PRNewswire) -

- More Than 1.2 Million Europeans Die of Smoking-Related DiseasesEach Year; An Estimated US$500 Billion in Global Health-Related Costsby 2010

- Medical Expert: 'Helping smokers quit is one of the mostimportant things a physician can do to improve their patients'overall health and reduce the risk of developing serious chronicconditions.'

Pfizer Inc said today that the Committee for Medicinal Productsfor Human Use (CHMP) of the European Medicines Evaluation Agencyissued a positive opinion recommending marketing authorization ofChampix(R) (varenicline), a novel pill for the treatment of smokingcessation.

The CHMP's positive recommendation will be reviewed by theEuropean Commission, which has authority to approve medicines for theEuropean Union. Pfizer anticipates a final decision from theCommission in the coming months.

Discovered and developed by Pfizer, Champix is a pill specificallydesigned as an aid to smoking cessation. Champix is believed to workby reducing the severity of the smoker's craving and many withdrawalsymptoms from nicotine. Moreover, if a person smokes a cigarettewhile receiving treatment, Champix has the potential to diminish thesense of satisfaction associated with smoking.

"Globally, it is expected that half a billion people alive todaywill die from smoking-related causes," said Dr. Joseph Feczko,Pfizer's chief medical officer. "Champix represents a significant newdiscovery in the arena of smoking cessation research. Pfizer ispleased that the CHMP has recognized the potential therapeuticbenefit of Champix in addressing this serious public health issue."

Smoking, the leading cause of preventable death worldwide, isresponsible for five million deaths worldwide each year. In Europealone, more than 1.2 million people die each year from a smokingrelated disease. By 2010, the WHO estimates the annual global cost oftobacco-related illness to be approximately US$500 billion.

"When it comes to smoking, preventive medicine is truly the bestmedicine. Smoking harms nearly every organ in the body and is thecause of many diseases including cardiovascular disease, cancer andrespiratory disease," said Dr. Serena Tonstad, Champix clinical trialinvestigator and head physician, Department of Preventive Cardiology,Ulleval University Hospital, Norway. "Helping smokers quit is one ofthe most important things a physician can do to improve theirpatients' overall health and reduce their risk of developing seriouschronic conditions."

The medication, varenicline, with tradename Chantix(TM)(varenicline) in the United States, received U.S. Food and DrugAdministration approval as an aid to smoking cessation in May 2006.In clinical trials, varenicline was generally well tolerated withoverall discontinuation rates similar to placebo. The most frequentside effects included nausea, headache, trouble sleeping and changesin dreaming.

US patients and health care providers can visit www.chantix.com orcall +1-877-CHANTIX and register to receive more information aboutCHANTIX. For prescribing information, please visit www.chantix.com.

DISCLOSURE NOTICE: The information contained in this release is asof July 28, 2006. The Company assumes no obligation to update anyforward-looking statements contained in this release as a result ofnew information or future events or developments.

This release contains forward-looking information about Champixthat involves substantial risks and uncertainties. A description ofthese risks and uncertainties can be found in the Company's AnnualReport on Form 10-K for the fiscal year ended December 31, 2005 andin its reports on Forms 10-Q and 8-K.

Web site: http://www.pfizer.com

ots Originaltext: Pfizer Inc.Im Internet recherchierbar: http://www.presseportal.de

Contact:Shreya Prudlo, +1-212-733-4889. Company News On-Call: Pfizer's pressreleases are available through PR Newswire's Company News On-Call service on PRN's Web Site. Visit http://www.prnewswire.com/comp/688250.html Photo: A free corporate logo to accompany this story is available immediately via Wieck Photo Database to any media with telephoto receiver or electronic darkroom, PC or Macintosh, that can accept overhead transmissions. To retrieve a logo, please call +1-972-392-0888. Company News On-Call: http://www.prnewswire.com/comp/688250.html

Pfizer Inc.

Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs
   © 2003-2013 med-kolleg.de Gesundheitsportal PFIZER'S CHAMPIX(R) RECEIVES POSITIVE OPINION FROM CHMP FOR THE TREATMENT OF SMOKING CESSATION